Published in Cell Cycle on September 09, 2003
Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol (2009) 1.56
Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology (2007) 1.19
Atypical E2F activity coordinates PHR1 photolyase gene transcription with endoreduplication onset. EMBO J (2010) 1.00
Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. J Biol Chem (2009) 0.97
RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene (2009) 0.95
KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget (2015) 0.82
A novel E2F-like protein involved in transcriptional activation of cyst wall protein genes in Giardia lamblia. J Biol Chem (2011) 0.81
E2F8 is a Potential Therapeutic Target for Hepatocellular Carcinoma. J Cancer (2017) 0.75
Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol (2003) 3.12
Arginine methylation regulates the p53 response. Nat Cell Biol (2008) 2.94
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol (2011) 2.28
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys (2003) 1.73
The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) (2004) 1.72
Atypical E2F activity restrains APC/CCCS52A2 function obligatory for endocycle onset. Proc Natl Acad Sci U S A (2008) 1.70
E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene (2005) 1.69
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
DNA-damage response control of E2F7 and E2F8. EMBO Rep (2008) 1.60
Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today (2006) 1.51
E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene (2004) 1.44
The yin and yang of E2F-1: balancing life and death. Nat Cell Biol (2003) 1.40
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol (2008) 1.38
Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep (2006) 1.33
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol (2006) 1.31
Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett (2009) 1.31
Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol (2004) 1.29
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J (2010) 1.25
The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun (2005) 1.22
A new effector pathway links ATM kinase with the DNA damage response. Nat Cell Biol (2004) 1.17
DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep (2006) 1.14
Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1. Mol Cell (2013) 1.12
A transcription co-factor integrates cell adhesion and motility with the p53 response. Proc Natl Acad Sci U S A (2009) 1.11
p14(ARF) regulates E2F activity. Oncogene (2002) 0.99
p53 ubiquitination by Mdm2: a never ending tail? DNA Repair (Amst) (2009) 0.99
A transcription cofactor required for the heat-shock response. EMBO Rep (2008) 0.99
ATM and Chk2 kinase target the p53 cofactor Strap. EMBO Rep (2008) 0.95
p53 methylation--the Arg-ument is clear. Cell Cycle (2009) 0.90
NEDDylation regulates E2F-1-dependent transcription. EMBO Rep (2012) 0.89
Actin nucleators in the nucleus: an emerging theme. J Cell Sci (2012) 0.87
14-3-3 proteins integrate E2F activity with the DNA damage response. EMBO J (2006) 0.87
The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structure. Proc Natl Acad Sci U S A (2012) 0.83
Mdm2 widens its repertoire. Cell Cycle (2007) 0.83
The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov Today (2003) 0.81
Actin nucleation by a transcription co-factor that links cytoskeletal events with the p53 response. Cell Cycle (2010) 0.80
E2F-7 couples DNA damage-dependent transcription with the DNA repair process. Cell Cycle (2013) 0.78
Cell cycle control by a methylation-phosphorylation switch. Cell Cycle (2011) 0.78
Signalling DNA damage by regulating p53 co-factor activity. Cell Cycle (2005) 0.78
Lysine methylation and the regulation of p53. Essays Biochem (2012) 0.78
Histone deacetylase inhibitors in psoriasis therapy. Curr Drug Targets Inflamm Allergy (2004) 0.77
Drug discovery and the p53 family. Prog Cell Cycle Res (2003) 0.77
Strap: a versatile transcription co-factor. Cell Cycle (2008) 0.77
A mismatched role for Bcl-2. Nat Cell Biol (2005) 0.75
T-ARG-eting E2F-1 growth control. Cell Cycle (2012) 0.75
E2F proteins. Curr Biol (2002) 0.75